While the recently approved first malaria vaccine provides new hope with a reduction in deadly severe malaria, decreasing the disease burden towards elimination requires highly effective drug treatment. However, treatment efficacy is constantly challenged by the capacity of Plasmodium falciparum parasites to develop resistance. The present artemisinin-based combination therapy is no exception. As the portfolio ...